Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
Status:
Terminated
Trial end date:
2021-01-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if PF-06687234 is effective and safe as add-on
therapy to infliximab in subjects with active ulcerative colitis who are not in remission.